NCT01498952

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

A Phase 1b/2, Open-label, Randomized Study of MEDI-573 in Combination With Sorafenib Verses Sorafenib Alone in Adult Subjects With Unresectable or Metastatic Hepatocellular Carcinoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).

Conditions

• Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Interventions

Type	Name	Description
DRUG	MEDI-573 (1 of 3 doses)	MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
DRUG	Sorafenib	Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor

Timeline

• Start date: 2012-01-17
• Primary completion: 2013-04-09
• Completion: 2013-04-09
• First posted: 2011-12-26
• Last updated: 2019-02-19
• Results posted: 2019-02-19

Locations

3 sites across 1 country: United States